Novo Nordisk's Options Market Is Bracing for a Rare Double-Digit Swing
Published on 08/03/2026 at 08:41 | Redaktion boerse-global.de
Investors in Novo Nordisk are heading into Wednesday's interim results with the kind of nervous energy usually reserved for binary events. The Danish drugmaker's shares have been battered by a failed late-stage trial, a high-profile investor exit, and the looming shadow of US price negotiations — and the derivatives market is pricing in a move that would rank among the year's most dramatic.
A Failed Trial That Changed the Conversation
The trouble began on Friday, when the Copenhagen-listed shares tumbled 8.48 percent to EUR 40.90. The trigger was the ZEUS Phase 3 study, which tested whether the investigational drug ziltivekimab could reduce major cardiovascular events in patients with chronic kidney disease and atherosclerosis. The result was stark: a hazard ratio of 0.99, meaning the drug performed essentially no better than placebo.
Novo Nordisk has already flagged a non-cash impairment charge for the program in the third quarter of 2026, though it has not disclosed the size. The setback has cast doubt on the company's ability to diversify beyond its diabetes and obesity franchises — a question that now looms large over the earnings call.
Lazard's Exit Adds to the Gloom
Over the weekend, regulatory filings added another layer of pressure. Lazard Asset Management disclosed on August 2 that it had slashed its position by roughly 89.2 percent, selling 767,290 shares and leaving it with just 92,516. The retreat stands in contrast to moves by Boston Partners and Arrowstreet Capital, both of which have recently built new positions. Still, the departure of a name like Lazard is hard to shrug off, and it is likely to intensify the debate about Novo Nordisk's growth prospects beyond its core weight-loss and diabetes products.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The Medicare Clock Is Ticking
Meanwhile, a regulatory deadline has quietly passed with direct implications for the business model. August 1 marked the end of the statutory window for the second round of US Medicare price negotiations under the Inflation Reduction Act. Among the 15 high-spend drugs selected are Ozempic and Wegovy. The Centers for Medicare & Medicaid Services is expected to publish the resulting "maximum fair prices" by early September, with the new rates taking effect on January 1, 2027. Industry estimates suggest Wegovy's list price could be cut by roughly half to remain eligible for federal health programs.
What the Options Market Is Saying
According to Saxo Bank, options pricing on the US-listed shares implies an expected move of around eight percent around the earnings date — a trading range of roughly USD 44.90 to USD 52.60. That estimate includes several days of drift beyond the actual report. Historical reactions have been smaller: after the last two quarterly releases, the stock fell 6.7 percent and 5.4 percent respectively on the following day, per Bloomberg data cited by Saxo. The market is clearly anticipating something bigger this time.
A Lower Bar, but a Divided Analyst Community
Expectations have been reset in the run-up to the report. Consensus estimates for quarterly earnings per share have been cut by about 24 percent over the past year, to roughly DKK 5.02 — a lower hurdle that makes a positive surprise more achievable.
Yet the analyst community remains deeply split. Among 26 analysts covering the Copenhagen-listed B-shares, the average rating is "hold," with a mean price target of DKK 317.20. The range of individual targets, from DKK 200 to DKK 453, underscores how uncertain the outcome of the obesity race against Eli Lilly has become. Across the Atlantic, a broader panel of 37 analysts is somewhat more optimistic, with a 68 percent buy rating and an average 12-month target of USD 51.19.
The Competitive Pressure Is Building
Eli Lilly's positive Phase 3 data for retatrutide, released on July 23, has sharpened the competitive picture. Novo Nordisk still commands roughly 89 percent of the US market for oral GLP-1 treatments with its oral Wegovy pill, launched in January. But Lilly's injectable challenger is closing the gap, and the dynamics of that race are likely to dominate analyst questions on Wednesday.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Since the first-quarter results, the US-listed shares have risen about 8.7 percent. A raise to the full-year guidance is widely expected and may already be priced in. That leaves management's commentary on US pricing trends and the pace of the international rollout of the Wegovy pill as the more consequential variables.
A Defining Test
The combination of lowered earnings expectations and an anticipated guidance lift suggests the market's reaction may hinge less on the headline numbers than on how management frames the road ahead. The elevated implied volatility in the options market reflects just how binary investors view this moment. Wednesday, August 5, will test whether the growth story around the oral Wegovy pill can offset the mounting pressure from competition, pricing, and a pipeline setback that has already shaken confidence.
Ad
Novo Nordisk Stock: New Analysis - 3 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
